709028-29-5

Upstream product

• 709028-25-1 1-(3-allyl-2,4-dihydroxy-phenyl)-2,2,2-trifluoro-ethanone 
• 91361-78-3 3-chloro-4-dimethylcarbamoylthio-phenylacetic acid methyl ester 
• 91373-91-0 (3-chloro-4-dimethylthiocarbamoyloxyphenyl)acetic acid methyl ester 
• 57017-95-5 methyl 3-chloro-4-hydroxyphenylacetate 
• 315-44-6 2,4-dihydroxy-1’,1’,1’-trifluoroacetophenone 
• 65239-69-2 2,4-dihydroxy-3-propyl-1',1',1'-trifluoroacetophenone 
• 194792-52-4 methyl 3-chloro-4-(3-bromopropylthio)-phenylacetate 

Downstream Products

• 194608-89-4 {3-chloro-4-[3-(7-propyl-3-trifluoromethyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 
• 709028-30-8 {3-Chloro-4-[3-(3-hydroxy-2-propyl-4-{2,2,2-trifluoro-1-[(Z)-hydroxyimino]-ethyl}-phenoxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 

Relevant academic research and scientific papers

Phenylacetic acid derivatives as hPPAR agonists

Beginning with the weakly active lead structure 1, a new series of hPPAR agonists was developed. In vivo glucose and triglyceride lowering activity was obtained by homologation and oxamination to 3, then conversion to substituted benzisoxazoles 4 and 5. F